Compare CMRE & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMRE | NKTR |
|---|---|---|
| Founded | 1974 | 1990 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2010 | 1996 |
| Metric | CMRE | NKTR |
|---|---|---|
| Price | $15.37 | $71.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $12.00 | ★ $146.67 |
| AVG Volume (30 Days) | 324.0K | ★ 515.9K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $307,711,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.55 | ★ N/A |
| Revenue Growth | N/A | ★ 86.00 |
| 52 Week Low | $10.84 | $27.87 |
| 52 Week High | $18.06 | $109.00 |
| Indicator | CMRE | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 54.31 | 46.71 |
| Support Level | $15.16 | $70.48 |
| Resistance Level | $15.86 | $76.49 |
| Average True Range (ATR) | 0.44 | 3.00 |
| MACD | 0.06 | -0.55 |
| Stochastic Oscillator | 73.33 | 24.10 |
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and others. The company provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.